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Case Report
Post-transplant lymphoproliferative disorder
after kidney transplantation: time to adopt
monitoring of Epstein-Barr virus?
Pauline Biller1, Lucienne Michaux2, Luc De Pauw3, Alessandra Camboni4,
Michel Mourad3, Nada Kanaan1
1Division of Nephrology, 2Division of Hematology, 3Division of Abdominal Surgery and Transplantation,
4Division of Pathology, Cliniques Universitaires Saint-Luc, Universite´ Catholique de Louvain Brussels, Belgium
Although post-transplant lymphoproliferative disorder is a classical complication encountered after kidney
transplantation, its diagnosis can still be challenging and its outcome life-threatening. Most cases are
related to Epstein-Barr virus (EBV) infection and occur mainly in the first year post-transplant, favoured by
the seronegative EBV status of the recipient transplanted with a kidney from a seropositive donor, and
strong immunosuppression. We report the case of a young kidney-pancreas transplant recipient who
developed post-transplant lymphoproliferative disorder (PTLD) early after transplantation, with a rapid fatal
issue. We review the pathogenesis, clinical presentation, and management of PTLD with a focus on
prevention.
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Background
Kidney transplantation is the preferred treatment
option for patients with end-stage renal disease.1
With increasingly potent immunosuppressive therapy,
the incidence of acute rejection has decreased over the
past years, leading to better graft and patient survival.
However, strong immunosuppression after transplan-
tation is associated with high morbidity and mortality
related to increased susceptibility to infections and
cancers. Post-transplant lymphoproliferative disorder
(PTLD) is a classical complication encountered after
transplantation that can be life-threatening. Most
cases are associated with Epstein-Barr virus (EBV)
infection. Indeed, impaired T-cell immunity resulting
from immunosuppressive treatment is unable to
restrain proliferation of B cells infected by EBV,
leading to uncontrolled proliferation of EBV-infected
lymphocytes.2
We report the case of a young kidney-pancreas
transplant recipient who developed PTLD early after
transplantation, with a rapid fatal issue. We review the
pathogenesis, clinical presentation, and management
of PTLD with a focus on prevention.
Case Report
A 32-year-old woman was transplanted in October
2012 with a combined kidney-pancreas graft from a
deceased donor for end-stage renal disease secondary to
diabetic nephropathy. Her past medical history was
mainly characterized by type 1 diabetes diagnosed at
age 12, complicated with retinopathy, neuropathy,
dysautonomia (orthostatic hypotension and gastropar-
esis), and chronic kidney disease requiring haemodia-
lysis from February 2012. Her serostatus at
transplantation was negative for both EBV and
CMV. The serostatus of the donor was positive for
EBV and negative for CMV. At transplantation, she
was administered an induction therapy with thymoglo-
bulin. Serum creatinine and glycemia rapidly normal-
ized. At discharge, treatment included tacrolimus
(14 mg q.d), mycophenolate mofetil (MMF) (500 mg
b.i.d), methylprednisolone (4 mg q.d), trimethoprim-
sulfametoxazole (800 mg 36/week), acetylsalicylic acid
(100 mg q.d) and ranitidine (150 mg q.d).
Fifteen days after transplantation, she was hospita-
lised for fever (38.3uC) with chills, and complained of
diarrhoea and abdominal pain. Her blood tests were
normal, including C-reactive protein level at 0.4 mg/
dl. A complete evaluation including abdominal and
chest computed tomography with contrast injection
was not contributory. Stool culture revealed Clostri-
dium difficile for which metronidazole was prescribed.
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Fever disappeared and the patient was discharged. At
the outpatient clinic, she continued to complain of
persistent diarrhoea. MMF was replaced by MMF
delayed-release tablets, with no improvement. She was
hospitalised 2 weeks later for a check-up. Stool cultures
remained sterile. Laboratory results as well as CMV
polymerase chain reaction (PCR) were unremarkable.
MMF dosage was in the therapeutic range. Colo-
noscopy and colonic biopsies were normal; gastro-
scopy showed a fungal infection for which fluconazole
was started. A celiac disease and malabsorption were
ruled out. She was discharged but readmitted 3 weeks
later for intermittent fever (37.5uC), sore throat,
dysphagia, arthralgias and persistent diarrhoea with
abdominal pain. Clinical examination was unremark-
able, although the patient condition was altered. Blood
tests showed increased C-reactive protein level
(11.3 mg/dl), hypoalbuminemia, normal liver enzymes,
and cholestasis (a twofold increase in gamma-glutamyl
transferase and alkaline phosphatase values). Lactate
dehydrogenase was increased (363 UI/l; normal value
(NV) ,240). A positron-emission computed tomogra-
phy showed pathological fluoro-deoxy-glucose (FDG)
uptake in the abdomen, liver, lungs, bones, retro-
peritoneal, cervical and in both kidneys (Fig. 1)
suggestive in that context of stage IV lymphoma.
EBV PCR showed a viral load of 28 924 copies/mg
DNA. Excision of a 2 cm inguinal lymph node was
performed. Grossly, the lymph node was necrotic.
Microscopic examination identified a monomorphic B-
cell PTLD with histological and immunophenotypic
aspects of a diffuse large B-cell lymphoma CD20z
related to EBV (Fig. 2).3 It was staged IVBb according
to Ann Arbor, and the age-adjusted international
prognostic index was calculated at III. MMF was
immediately stopped and tacrolimus doses were
reduced by half. An R-CHOP like chemotherapy
including rituximab, cyclophosphamide and adriamy-
cin was scheduled; it was decided to avoid vincristine
because of the existing neuropathy. Unfortunately, the
patient developed acute abdominal pain secondary to
intestinal perforation of tumours requiring resection of
part of the small intestine (Fig. 3). Severe sepsis
consecutive to peritonitis contributed to acute renal
function deterioration. Chemotherapy was nevertheless
started, complicated by febrile neutropenia. Pulmonary
aspergillosis and systemic candidemia were diagnosed
and treated, but the patient rapidly succumbed at the
intensive care unit.
Discussion
Post-transplant lymphoproliferative disorder encom-
passes a wide spectrum of lymphoproliferative
disorders that range from infectious mononucleosis-
like lesions and plasmacytic hyperplasia (early
lesions) to highly invasive malignant lymphoma
(monomorphic PTLD or classical Hodgkin lym-
phoma-type PTLD).3 It is a relatively common
malignancy after transplantation, ranking first in
children and second in adults after skin cancer.4,5
Although EBV-negative PTLD does occur, most
cases are related to EBV infection and occur mainly
in the first year post-transplant, in response to either
primary infection with EBV or to re-activation of
previously acquired EBV. Decreased T cell immune
surveillance induced by immunosuppression favours
Figure 1 Positron emission computed tomography imaging after intravenous injection of 18F-fluorodeoxyglucose (18FDG).
Coronal views (non-enhanced low-dose CT (A), FDG positron emission tomography (C) and fused images (B)) show multiple
scattered foci of pathological accumulation of 18FDG (arrow) in the native kidneys, liver, abdomen, lungs, upper part of the
oesophagus suggestive of stage IV lymphoma.
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proliferation of EBV-infected B lymphocytes.6 The
main risk factors for PTLD include EBV serostatus
of the recipient and the degree of T-cell immunosup-
pression.7–10 Our patient had both risk factors: heavy
immunosuppression due to induction therapy and to
the early post-transplant intense immunosuppression,
and EBV-negative serostatus receiving kidney and
pancreas organs from an EBV-positive donor.2
The clinical presentation of patients with PTLD
varies from non-specific symptoms such as fatigue,
weight loss, night sweats, and fever to more
severe organ dysfunction or infectious complications.
Commonly, patients present a mononucleosis-like
syndrome associating lymphadenopathy, weight loss,
fever and increased transaminase levels, or with
gastrointestinal symptoms ranging from diffuse
abdominal discomfort, loose bowel movement or
diarrhoea to gastrointestinal bleeding or bowel
perforation. Up to two-third of patients have extra-
nodal organ involvement at presentation, that can
involve the gastrointestinal tract, lungs, skin, liver,
allograft, and central nervous system (CNS). In this
latter case, the CNS can be the only site of the
disease. Not infrequently, infiltration of the allograft
can lead to allograft dysfunction.8 Our patient
presented with abdominal complaints and diarrhoea
within the first month post-transplantation. A total
digestive evaluation including abdominal computed
tomography, colonoscopy and colon biopsies failed
to diagnose PTLD, until she presented a few weeks
later with a fulminant disseminated disease.
The cornerstone of therapy for PTLD is a reduction
of immunosuppression. This strategy helps restoring
T-cell-mediated immune response with the develop-
ment of cytotoxic T lymphocytes against EBV-infected
cells. As in our patient, mycophenolate mofetil is
usually discontinued first, and calcineurin inhibitors
doses reduced.7 Rituximab, a humanized chimeric
anti-CD20 antibody targeting B cells is used as an
adjunct to reduction of immunosuppression or che-
motherapy.11 Risk factors for a poor response to anti-
B cell therapy include late-onset PTLD (.1 year after
transplant), CNS involvement, involvement of multi-
ple viscera, and PTLD that lack expression of CD20.12
Figure 2 Monomorphic B-cell PTLD with histological and immunophenotypic aspects of a diffuse large B-cell lymphoma
CD20z related to EBV. Microscopic examination of the excised lymph node showed large areas of coagulative necrosis and a
proliferation of polymorphic lymphoid cells of medium to large size with a voluminous nucleus containing one or more nucleoli
(a). The tumour cells expressed CD20 (b), Bcl2, MUM1, c-Myc and occasionally CD30. Bcl6, CD15 and CD3 were negative. The
proliferation index based on the Ki-67 immunostaining was 70% (c). Positive signals of EBV were detected in neoplastic cells by
in situ hybridization with EBER probe (d).
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In patients with rapidly progressive or life-threatening
disease, chemotherapy is used with regimens including
among others CHOP (cyclophosphamide, doxorubi-
cin, vincristine and prednisone) with or without
rituximab. Though effective, these chemotherapies
increase the risk of infections and other complications,
resulting in significant morbidity and mortality.8 Our
patient prognosis was poor given the disseminated
disease involving multiple organs complicated by
intestinal perforation and she died from sepsis in a
context of chemotherapy-induced neutropenia.
Would the monitoring of EBV viral loads after
transplantation have changed the course of events
in our patient? Kidney Disease Improving Global
Outcomes suggests monitoring high-risk kidney
transplant recipients (donor EBV seropositive/recipi-
ent seronegative) for EBV by quantitative PCR at
least monthly for the first 3–6 months after trans-
plantation, then every 3 months until the end of the
first post-transplant year, and, additionally, after
treatment for acute rejection.13 Because EBV viral
load becomes positive 4–16 weeks prior to develop-
ment of PTLD,14 a rising EBV load would help
identify patients in whom intervention may prevent
PTLD.15 In these patients, pre-emptive reduction of
immunosuppression has resulted in a decreased
incidence of EBV disease and PTLD compared to
historical controls and, as suggested by Kidney
Disease Improving Global Outcomes guidelines,13 is
currently the optimal available preventive strategy.2
Thus our high-risk patient would probably have
benefited from EBV load surveillance in the context
of persistent diarrhoea, altered physical condition,
with a possible milder PTLD onset in response to
preventive reduction of immunosuppression. This
dramatic case brought us to implement monito-
ring for EBV by quantitative PCR in high-risk
seronegative kidney transplant recipients. Because
the assay is not reimbursed by our national medi-
cal insurance, we have opted to monitor EBV PCR at
1, 3, 6, 9 and 12 months post-transplantation.
Monitoring is performed in our academic hospital
to avoid interlaboratory variability. Conditions of
reimbursement of the assay vary in different coun-
tries and are probably the current bottlenecks in the
implementation of EBV viral load monitoring.
Conclusion
In conclusion, this case highlights the following points
regarding PTLD occurring after renal transplantation.
1. Post-transplant lymphoproliferative disorder can
be a life-threatening complication and is an important
cause of mortality after transplantation.
2. Kidney transplant recipients seronegative for
EBV who receive organs from EBV seropositive donors
are at high risk for EBV disease and PTLD.
3. Epstein-Barr virus disease can present with several
non-specific manifestations before the onset of PTLD,
leading to delayed diagnosis.
4. Monitoring high-risk kidney transplant recipients
for EBV by quantitative PCR during the first post-
transplant year and in case of altered condition would
probably help to diagnose PTLD early, and should be
adopted whenever possible. An immediate decrease in
immunosuppression may then prevent disseminated
fatal disease.
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